162 related articles for article (PubMed ID: 14977853)
1. NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven.
Dick RA; Yu X; Kensler TW
Clin Cancer Res; 2004 Feb; 10(4):1492-9. PubMed ID: 14977853
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea derivatives of irofulven with improved antitumor efficacy.
Staake MD; Kashinatham A; McMorris TC; Estes LA; Kelner MJ
Bioorg Med Chem Lett; 2016 Apr; 26(7):1836-8. PubMed ID: 26922141
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
Wiltshire T; Senft J; Wang Y; Konat GW; Wenger SL; Reed E; Wang W
Mol Pharmacol; 2007 Apr; 71(4):1051-60. PubMed ID: 17229870
[TBL] [Abstract][Full Text] [Related]
5. On the mechanism of toxicity of illudins: the role of glutathione.
McMorris TC; Kelner MJ; Wang W; Moon S; Taetle R
Chem Res Toxicol; 1990; 3(6):574-9. PubMed ID: 2103329
[TBL] [Abstract][Full Text] [Related]
6. Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.
Poindessous V; Koeppel F; Raymond E; Comisso M; Waters SJ; Larsen AK
Clin Cancer Res; 2003 Jul; 9(7):2817-25. PubMed ID: 12855662
[TBL] [Abstract][Full Text] [Related]
7. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Kelner MJ; McMorris TC; Rojas RJ; Trani NA; Estes L
Cancer Chemother Pharmacol; 2002 May; 49(5):412-8. PubMed ID: 11976836
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity.
Kelner MJ; McMorris TC; Taetle R
J Natl Cancer Inst; 1990 Oct; 82(19):1562-5. PubMed ID: 2402017
[TBL] [Abstract][Full Text] [Related]
10. Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven.
Wang Y; Wiltshire T; Senft J; Wenger SL; Reed E; Wang W
Mol Cancer Ther; 2006 Dec; 5(12):3153-61. PubMed ID: 17172419
[TBL] [Abstract][Full Text] [Related]
11. Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases.
Wang W; Waters SJ; MacDonald JR; Roth C; Shentu S; Freeman J; Von Hoff DD; Miller AR
Anticancer Res; 2002; 22(2A):559-64. PubMed ID: 12014623
[TBL] [Abstract][Full Text] [Related]
12. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic trial of irofulven.
Thomas JP; Arzoomanian R; Alberti D; Feierabend C; Binger K; Tutsch KD; Steele T; Marnocha R; Smith C; Smith S; MacDonald J; Wilding G; Bailey H
Cancer Chemother Pharmacol; 2001 Dec; 48(6):467-72. PubMed ID: 11800027
[TBL] [Abstract][Full Text] [Related]
14. The catalytic and kinetic mechanisms of NADPH-dependent alkenal/one oxidoreductase.
Dick RA; Kensler TW
J Biol Chem; 2004 Apr; 279(17):17269-77. PubMed ID: 14966122
[TBL] [Abstract][Full Text] [Related]
15. Antioxidative function and substrate specificity of NAD(P)H-dependent alkenal/one oxidoreductase. A new role for leukotriene B4 12-hydroxydehydrogenase/15-oxoprostaglandin 13-reductase.
Dick RA; Kwak MK; Sutter TR; Kensler TW
J Biol Chem; 2001 Nov; 276(44):40803-10. PubMed ID: 11524419
[TBL] [Abstract][Full Text] [Related]
16. Irofulven (MGI Pharma).
Baekelandt M
Curr Opin Investig Drugs; 2002 Oct; 3(10):1517-26. PubMed ID: 12431030
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways.
Jaspers NG; Raams A; Kelner MJ; Ng JM; Yamashita YM; Takeda S; McMorris TC; Hoeijmakers JH
DNA Repair (Amst); 2002 Dec; 1(12):1027-38. PubMed ID: 12531012
[TBL] [Abstract][Full Text] [Related]
18. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
19. Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks.
Chaverra-Muñoz L; Briem T; Hüttel S
Microb Cell Fact; 2022 May; 21(1):98. PubMed ID: 35643529
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of illudins as anticancer agents.
Kelner MJ; McMorris TC; Beck WT; Zamora JM; Taetle R
Cancer Res; 1987 Jun; 47(12):3186-9. PubMed ID: 3472654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
